Certara’s combined PBPK/QSP model predicts safety and efficacy biomarker outcomes in Alzheimer’s Disease, as demonstrated in recent lecanemab work with Eisai 白皮书
Immunogenicity Prediction and Dose Optimization using Clinically-Validated In Silico Modeling and Simulation 白皮书